TETRAPHASE PHARMACEUTICALS INC Selling, General and Administrative Expense
TETRAPHASE PHARMACEUTICALS INC reported Selling, General and Administrative Expense of $10.67 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2020-05-07
- TETRAPHASE PHARMACEUTICALS INC selling, general and administrative expense for the quarter ending 2020-03-31 was $10.67M, a 19.87% decline year-over-year.
- TETRAPHASE PHARMACEUTICALS INC selling, general and administrative expense for the quarter ending 2019-12-31 was $9.27M, a 37.08% decline year-over-year.
- TETRAPHASE PHARMACEUTICALS INC selling, general and administrative expense for the quarter ending 2019-09-30 was $11.35M, a 19.71% increase year-over-year.
- TETRAPHASE PHARMACEUTICALS INC selling, general and administrative expense for the quarter ending 2019-06-30 was $15.11M, a 110.93% increase year-over-year.
- TETRAPHASE PHARMACEUTICALS INC selling, general and administrative expense for fiscal 2019 was $49.04M, a 32.27% increase from fiscal 2018.
- TETRAPHASE PHARMACEUTICALS INC selling, general and administrative expense for fiscal 2018 was $37.08M, a 56.61% increase from fiscal 2017.
- TETRAPHASE PHARMACEUTICALS INC selling, general and administrative expense for fiscal 2017 was $23.68M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2020-03-31 | $10.67M 10-Q · filed 2020-05-07 | $19.93M derived: sum of 2 quarters · filed 2020-05-07 | $31.28M derived: sum of 3 quarters · filed 2020-05-07 | $46.40M derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-12-31 | $9.27M 10-K · filed 2020-03-12 | $20.62M derived: sum of 2 quarters · filed 2020-03-12 | $35.73M derived: sum of 3 quarters · filed 2020-03-12 | $49.04M 10-K · filed 2020-03-12 |
| 2019-09-30 | $11.35M 10-K · filed 2020-03-12 | $26.46M derived: sum of 2 quarters · filed 2020-03-12 | $39.78M 10-Q · filed 2019-11-12 | $54.50M derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-06-30 | $15.11M 10-K · filed 2020-03-12 | $28.43M 10-Q · filed 2019-08-08 | $43.15M derived: sum of 3 quarters · filed 2020-05-07 | $52.63M derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-03-31 | $13.31M 10-Q · filed 2020-05-07 | $28.04M derived: sum of 2 quarters · filed 2020-05-07 | $37.52M derived: sum of 3 quarters · filed 2020-05-07 | $44.69M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $14.73M 10-K · filed 2020-03-12 | $24.21M derived: sum of 2 quarters · filed 2020-03-12 | $31.37M derived: sum of 3 quarters · filed 2020-03-12 | $37.08M 10-K · filed 2020-03-12 |
| 2018-09-30 | $9.48M 10-K · filed 2020-03-12 | $16.65M derived: sum of 2 quarters · filed 2020-03-12 | $22.35M 10-Q · filed 2019-11-12 | $30.23M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $7.17M 10-K · filed 2020-03-12 | $12.87M 10-Q · filed 2019-08-08 | $20.75M derived: sum of 3 quarters · filed 2020-03-12 | $26.35M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | $5.71M 10-K · filed 2020-03-12 | $13.58M derived: sum of 2 quarters · filed 2020-03-12 | $19.18M derived: sum of 3 quarters · filed 2020-03-12 | $24.25M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | $7.88M 10-K · filed 2019-03-15 | $13.48M derived: sum of 2 quarters · filed 2019-03-15 | $18.54M derived: sum of 3 quarters · filed 2019-03-15 | $23.68M 10-K · filed 2019-03-15 |
| 2017-09-30 | $5.60M 10-K · filed 2019-03-15 | $10.66M derived: sum of 2 quarters · filed 2019-03-15 | $15.80M 10-Q · filed 2018-11-09 | |
| 2017-06-30 | $5.07M 10-K · filed 2019-03-15 | $10.20M derived: sum of 2 quarters · filed 2019-03-15 | ||
| 2017-03-31 | $5.13M 10-K · filed 2019-03-15 |